ArticleAnnals of surgical oncology2024
Evaluating the Effect of MarginProbe
Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ASO Author Reflections: Breast Surgeons and Non-palpable Lesions-A "Magnetic" Relationship.Annals of surgical oncology · 2026Article
- Intraoperative measurement of breast-conserving surgery margins: surgical application.Breast cancer research : BCR · 2026Review
- Detection of margin positivity in breast cancer using fluorescence and diffuse reflectance imaging.Journal of Taibah University Medical Sciences · 2026Article
- Time-Resolved Fluorescence and Diffuse Reflectance (TRF-DR) Spectroscopy for Heterogeneous Breast Tissue Classification and Tumor Margin Assessment.Journal of biophotonics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast conservation therapy is a widely accepted approach in treating breast cancer, yet the average re-excision rates are approximately 25% despite surgical advancements. The Food and Drug Administration (FDA)-approved MarginProbe
methodsA prospective cohort with MarginProbe
resultsWhen control was used for patient demographics and tumor characteristics, the findings showed that MarginProbe
conclusionsMarginProbe
Indexed as
Identifiers
39090489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.